Evidence map›Paper›PMID 29368550›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2018

Aurothioglucose does not improve alveolarization or elicit sustained Nrf2 activation in C57BL/6 models of bronchopulmonary dysplasia.

Qian Li, Rui Li, Stephanie B Wall, Katelyn Dunigan, Changchun Ren, Tamas Jilling, Lynette K Rogers, Trent E Tipple

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Aurothioglucose enhances proangiogenic pathway activation in lungs from room air and hyperoxia-exposed newborn mice.American journal of physiology. Lung cellular and molecular physiology · 2020
    Article
  9. Article
  10. Role of Nrf2 and Its Activators in Respiratory Diseases.Oxidative medicine and cellular longevity · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qian LiNeonatal Redox Biology Laboratory, University of Alabama at Birmingham , Birmingham, Alabama.
Rui LiNeonatal Redox Biology Laboratory, University of Alabama at Birmingham , Birmingham, Alabama.
Stephanie B WallNeonatal Redox Biology Laboratory, University of Alabama at Birmingham , Birmingham, Alabama.
Katelyn DuniganNeonatal Redox Biology Laboratory, University of Alabama at Birmingham , Birmingham, Alabama.
Changchun RenDepartment of Pediatrics, University of Alabama at Birmingham , Birmingham, Alabama.
Tamas JillingDepartment of Pediatrics, University of Alabama at Birmingham , Birmingham, Alabama.ORCID 0000-0002-6200-3851
Lynette K RogersCenter for Perinatal Research, Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Trent E TippleNeonatal Redox Biology Laboratory, University of Alabama at Birmingham , Birmingham, Alabama.
University of Alabama at Birmingham · USNationwide Children's Hospital · US

Funding

Targeting Thioredoxin Reductase-1 to Prevent Bronchopulmonary DysplasiaR01HL119280 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TIPPLE, TRENT · 2014 to 2018
$2.0M
Optimizing Therapeutic delivery of MicroRNAs to prevent chronic lung disease in Preterm infants.R01HD088033 · NICHD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI ROGERS, LYNETTE KAY · 2017 to 2021
$1.6M
NHLBI NIH HHS R01 HL119280NICHD NIH HHS R01 HD088033
6 · The paper itself

Abstract

We previously showed that the thioredoxin reductase-1 (TrxR1) inhibitor aurothioglucose (ATG) improves alveolarization in hyperoxia-exposed newborn C3H/HeN mice. Our data supported a mechanism by which the protective effects of ATG are mediated via sustained nuclear factor E2-related factor 2 (Nrf2) activation in hyperoxia-exposed C3H/HeN mice 72 h after ATG administration. Given that inbred mouse strains have differential sensitivity and endogenous Nrf2 activation by hyperoxia, the present studies utilized two C57BL/6 exposure models to evaluate the effects of ATG on lung development and Nrf2 activation. The first model (0-14 days) was used in our C3H/HeN studies and the 2nd model (4-14 days) is well characterized in C57BL/6 mice. ATG significantly inhibited lung TrxR1 activity in both models; however, there was no effect on parameters of alveolarization in C57BL/6 mice. In sharp contrast to C3H/HeN mice, there was no effect of ATG on pulmonary NADPH quinone oxidoreductase-1 ( Nqo1) and heme oxygenase-1 ( Hmox1) at 72 h in either C57BL/6 model. In conclusion, although ATG inhibited TrxR1 activity in the lungs of newborn C57BL/6 mice, effects on lung development and sustained Nrf2-dependent pulmonary responses were blunted. These findings also highlight the importance of strain-dependent hyperoxic sensitivity in evaluation of potential novel therapies.

Indexed as

AnimalsAnimals, NewbornAntirheumatic AgentsAurothioglucoseBronchopulmonary DysplasiaCells, CulturedFemaleGene Expression RegulationLungMaleMiceMice, Inbred C3HMice, Inbred C57BLNAD(P)H Dehydrogenase (Quinone)NF-E2-Related Factor 2Pulmonary AlveoliAntirheumatic AgentsAurothioglucoseNAD(P)H Dehydrogenase (Quinone)Nfe2l2 protein, mouseNF-E2-Related Factor 2Nqo1 protein, mouseThioredoxin Reductase 1Txnrd1 protein, mouseaurothioglucosebronchopulmonary dysplasiahyperoxianuclear factor (erythroid-derived-1)-like 2

Identifiers

PMID29368550
PMCPMC6008122
OpenAlexW2784806142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.